The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-08 and is reviewed periodically as new material appears.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
The two substrates of this enzyme are dihydrobunolol and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are bunolol, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (+/−)-5-[(tert-butylamino)-2'-hydroxypropoxy]-1,2,3,4-tetrahydro-1-naphthol:NADP+ oxidoreductase. This enzyme is also termed bunolol reductase.
== History == It was first used in 1795 shortly after the formation of the Orange Order and was the original system put together by the founding members of the Orange Order. The Grand Orange Lodge of Ireland disliked the ritualism and tried to suppress it as early as 1798 however, the main reason for the opposition to the Royal Arch Purple Degree was that many rural Lodges were practising other degrees in addition to the Royal Arch Purple degree and the gentry deemed this as unacceptable and realised the need for a central system of degrees. The Royal Arch Purple degree was practised in secrecy for a period after the Grand Lodge (in Dublin) deemed the degree illegal, however it was kept alive by the Lodges around County Armagh as it was the system of 'travel' closest to the original ritual put together by the founding members of the Orange Order in 1795. The Grand Lodge maintains their position in not recognising the degree to this day although it now, rather grudgingly, recognises the Royal Arch Purple as an official Order. It was re-constituted in 1911, with the explicit intentions of promoting the Reformed Faith, Charity amongst all men and maintaining historic Orangeism. It was granted its Royal title by the Duke of Cumberland, King Ernest Augustus of Hanover, who was the fifth son of King George III, and brother to King George IV and King William IV, whom he succeeded as King of Hanover.
=== Direct printing === Two different methods for the direct application of indigo were developed in England in the 18th century and remained in use well into the 19th century. The first method, known as "pencil blue" because it was most often applied by pencil or brush, could be used to achieve dark hues. Arsenic trisulfide and a thickener were added to the indigo vat. The arsenic compound delayed the oxidation of the indigo long enough to paint the dye onto fabrics.
The results of the work at Duke were impressive with one treated bird recovering to the point of being able to fly again. This was followed by the production of clinical-grade alpha-glucosidase in Chinese hamster ovary (CHO) cells and in the milk of transgenic rabbits. This work eventually culminated in the start of clinical trials with the first clinical trial including four babies receiving enzyme from rabbit milk at Erasmus MC Sophia Children's Hospital and three babies receiving enzyme grown in CHO cells at Duke University in 1999. The currently approved Myozyme is manufactured by Genzyme Corp. in Cambridge, Massachusetts. Its development was a complex process. Genzyme first partnered with Pharming Group NV which had managed to produce acid alpha-glucosidase from the milk of transgenic rabbits. They also partnered with a second group based at Duke University using Chinese hamster ovary cells. In 2001, Genzyme acquired Novazyme which was also working on this enzyme. Genzyme also had its product (Myozyme) grown in CHO cells under development. In November 2001, Genzyme chief executive Henri Termeer organised a systematic comparison of the various potential drugs in a mouse model of Pompe disease. It was found that the Duke enzyme was the most efficacious, followed by Myozyme. However, due to easier manufacture of Myozyme, work on the other products was discontinued.
The new 9th district, which previously encompassed southern portions of Houston and such suburbs as Missouri City and was represented by incumbent Democrat Al Green, has been relocated to the eastern portions of the Houston area as a result of redistricting; Green ran for reelection in the newly redrawn 18th district. The new district, which has a 58.6% Hispanic voting age population, covers such east and southeast Houston neighborhoods as Denver Harbor, Magnolia Park, Park Place and Edgebrook, as well as most of the suburbs of Pasadena, Baytown, Deer Park, La Porte, Galena Park, Channelview and Crosby, and exurban Liberty County including Cleveland, Liberty and Dayton. Donald Trump carried the district in all three of his elections - a 49.8% plurality in 2016, 53.7% in 2020, and 59.5% in 2024, and the district also gave Ted Cruz 54.4% of the vote in 2024.
Sources: en.wikipedia.org
The supernatant contains a mitogenic factor, a mitosis promoting factor, that is characterized heat and trypsin sensitivity, both of which characterize it as a peptide. Treatment of Schwann cells with the collected supernatant shows that it is a mitogenic factor and thus plays an important role in the proliferation of Schwann cells. Macrophages are also involved in the secretion factors that promote nerve regeneration. Macrophages secrete not only interleukin-1, a cytokine that induces expression of nerve growth factor (NGF) in Schwann cells but also an interleukin-1 receptor antagonist (IL-1ra). Expression of IL-1ra in mice with transected sciatic nerves via implantation of a tube releasing IL-1ra showed the regrowth of fewer myelinated and unmyelinated axons. Macrophage secretion of interleukin-1 is involved in stimulation of nerve regeneration.
== History == In February 2003, Nabil Seidah and Jae Byun, a scientist at the Clinical Research Institute of Montreal in Canada, discovered a novel human proprotein convertase, the gene for which was located on the short arm of chromosome 1. Meanwhile, a lab led by Catherine Boileau at the Necker–Enfants Malades Hospital in Paris had been following families with familial hypercholesterolaemia, a genetic condition that, in 90% of cases causes coronary artery disease (FRAMINGHAM study) and in 60% of cases may lead to an early death; they had identified a mutation on chromosome 1 carried by some of these families, but had been unable to identify the relevant gene. The labs got together and by the end of the year published their work, linking mutations in the gene, now identified as PCSK9, to the condition. In their paper, they speculated that the mutations might make the gene overactive. In that same year, investigators at Rockefeller University and University of Texas Southwestern had discovered the same protein in mice, and had worked out the novel pathway that regulates LDL cholesterol in which PCSK9 is involved, and it soon became clear that the mutations identified in France led to excessive PCSK9 activity, and thus excessive removal of the LDL receptor, leaving people carrying the mutations with too much LDL cholesterol. Meanwhile, Helen H. Hobbs and Jonathan Cohen at UT-Southwestern had been studying people with very high and very low cholesterol, and had been collecting DNA samples.
=== Expression in bacterial hosts === There currently are very few effective methods for expressing functional plant Rubisco in bacterial hosts for genetic manipulation studies. This is largely due to Rubisco's requirement of complex cellular machinery for its biogenesis and metabolic maintenance including the nuclear-encoded RbcS subunits, which are typically imported into chloroplasts as unfolded proteins. Furthermore, sufficient expression and interaction with Rubisco activase are major challenges as well. One successful method for expression of Rubisco in E. coli involves the co-expression of multiple chloroplast chaperones, though this has only been shown for Arabidopsis thaliana Rubisco.
=== 23 February === The Russian Ministry of Defense claimed that Ukraine was preparing to invade Transnistria and that Russian soldiers there would respond accordingly. Moldovan authorities pushed back against these claims.
Sources: en.wikipedia.org
The Fisher King (French: Roi Pêcheur) is a figure in the Arthurian legend, the last in a long line of British kings tasked with guarding the Holy Grail. The Fisher King is both the protector and physical embodiment of his lands, but a wound renders him impotent and his kingdom barren. Unable to walk or ride a horse, he is sometimes depicted as spending his time fishing while he awaits a hero who can heal him. Versions of the Grail King story vary widely, but the Fisher King, or the Maimed King (Roi Méhaigné), is typically depicted as being wounded in the groin, legs, or thigh. The healing of these wounds always depends upon the completion of a hero-knight's task. Besides the Holy Grail, the Lance of Longinus may feature as a key plot element. In some variants, a third character is introduced; this individual, unlike the hero-knight archetype, is ignorant of the King's power, but has the ability to save the king and land, or to doom it. As a literary character, the Fisher King originates in Chrétien de Troyes' unfinished writings of the adventures of the Grail Knight, Perceval. Many authors have endeavoured to complete and extend the work, resulting in various continuations. Major sources of the legend include Chrétien's Li Contes del Graal; Perceval, ou Le Conte du Graal (c. 1180–1190), Wauchier de Denain's First Continuation (c. 1190–1200), Robert de Boron's Didot-Perceval (c. 1191–1202), Peredur son of Efrawg (c. 1200), Perlesvaus (c. 1200), Wolfram von Eschenbach's Parzival (c. 1205), and Thomas Malory's Morte D'Arthur (c. 1400).
In all the places where they pretend to have the graveclothes, they show a large piece of linen by which the whole body, including the head, was covered, and, accordingly, the figure exhibited is that of an entire body. But the Evangelist John relates that Christ was buried, "as is the manner of the Jews to bury". What that manner was may be learned, not only from the Jews, by whom it is still observed, but also from their books, which explain what the ancient practice was. It was this: The body was wrapped up by itself as far as the shoulders, and then the head by itself was bound round with a napkin, tied by the four corners, into a knot. And this is expressed by the Evangelist, when he says that Peter saw the linen clothes in which the body had been wrapped lying in one place, and the napkin which had been wrapped about the head lying in another. The term napkin may mean either a handkerchief employed to wipe the face, or it may mean a shawl, but never means a large piece of linen in which the whole body may be wrapped. I have, however, used the term in the sense which they improperly give to it. On the whole, either the Evangelist John must have given a false account, or every one of them must be convicted of falsehood, thus making it manifest that they have too impudently imposed on the unlearned. Although pieces said to be of burial cloths of Jesus are held by at least four churches in France and three in Italy, none has gathered as much religious following as the Shroud of Turin.
=== Pseudovitamins and antivitamins === Pseudovitamin B12 refers to compounds that are corrinoids with a structure similar to the vitamin, but without vitamin activity. Pseudovitamin B12 is the majority corrinoid in spirulina, an algal dietary supplement sometimes erroneously claimed as having this vitamin activity. Antivitamin B12 compounds (often synthetic B12 analogues) not only have no vitamin action, but also actively interfere with the activity of true vitamin B12. The design of these compounds mainly involves the replacement of the metal ion with rhodium, nickel, or zinc, or may have an inactive ligand attached, such as 4-ethylphenyl. These compounds have the potential for use in analyzing B12 pathways or even attacking B12-dependent pathogens.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.